| Q64987328 | Association between Interleukin 35 Gene Single Nucleotide Polymorphisms and Systemic Lupus Erythematosus in a Chinese Han Population. |
| Q38598212 | Association of anti-CLIC2 and anti-HMGB1 autoantibodies with higher disease activity in systemic lupus erythematosus patients |
| Q37153407 | Cancer risk in immune-mediated inflammatory diseases (IMID). |
| Q28075268 | Cause and consequences of the activated type I interferon system in SLE |
| Q36869519 | Chinese Herbal Medicine (Zi Shen Qing) for Mild-to-Moderate Systematic Lupus Erythematosus: A Pilot Prospective, Single-Blinded, Randomized Controlled Study |
| Q88489749 | Circular RNA expression profile and potential function of hsa_circ_0045272 in systemic lupus erythematosus |
| Q30248816 | Circular RNAs and systemic lupus erythematosus. |
| Q64244673 | Circular RNAs in immune responses and immune diseases |
| Q87998045 | Clinical and laboratory aspects of dyslipidemia in Brazilian women with systemic lupus erythematosus |
| Q30234822 | Competitive endogenous RNA network: potential implication for systemic lupus erythematosus. |
| Q35786726 | Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies. |
| Q58908905 | Epstein-Barr virus and systemic lupus erythematosus |
| Q45357292 | Epstein-Barr virus early antigen diffuse (EBV-EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients. |
| Q37154847 | Epstein-Barr virus in systemic autoimmune diseases |
| Q64235364 | Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay |
| Q38286372 | Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus |
| Q54263338 | Immune responses to an early lytic cytomegalovirus antigen in systemic lupus erythematosus patients: T-cell responses, cytokine secretions and antibody status. |
| Q39607978 | Immunology, autoimmunity, and autoantibodies in Parkinson's disease |
| Q36784009 | Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients |
| Q52936645 | Increased expression of TLR2 in CD4(+) T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through histone modifications. |
| Q40501964 | Levels of serum procalcitonin and C-reactive protein for evaluating pulmonary bacterial infection in patients with lupus erythematosus |
| Q30588683 | Lipid anti-lipid antibody responses correlate with disease activity in systemic lupus erythematosus |
| Q49830970 | Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. |
| Q55554942 | Neuropsychiatric Involvement in Juvenile-Onset Systemic Lupus Erythematosus. |
| Q39258006 | Real-Time PCR of cytomegalovirus and Epstein-Barr virus in adult Egyptian patients with systemic lupus erythematosus |
| Q34478829 | Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients. |
| Q37116902 | Severity of dry eye syndrome is related to anti-dsDNA autoantibody in systemic lupus erythematosus patients without secondary Sjogren syndrome: A cross-sectional analysis |
| Q85072604 | Systemic lupus erythematosus and the SLE galaxy |
| Q39515619 | T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. |
| Q45021635 | The clinical manifestations and survival of systemic lupus erythematosus patients in Turkey: report from two centers |
| Q38257820 | The clinical utility of anti-ribosomal P autoantibodies in systemic lupus erythematosus |
| Q36219637 | Tolerogenic versus inflammatory activity of peripheral blood monocytes and dendritic cells subpopulations in systemic lupus erythematosus |
| Q42555303 | Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis |